Paulson & Co’s Sarepta Therapeutics SRPT Stock Holding History

Paulson & Co’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-78,101	Closed	-$2.31M	–	117
2017 Q1	$2.31M	Buy	+78,101	New	+$2.42M	0.03%	83

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

TCP

Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Paulson & Co's SRPT Position: Q2 2017 in Review

Paulson & Co sold out of Sarepta Therapeutics (SRPT) in Q2 2017, closing a stake of 78,101 shares — an estimated $2.31M sold.

Paulson & Co first reported a position in SRPT in Q1 2017 and held it in 1 quarter. The position peaked at $2.31M in Q1 2017. 189 funds tracked by Wall St. Rank hold SRPT as of Q2 2017.

Paulson & Co reported no remaining Sarepta Therapeutics position as of Q2 2017 after selling out during the quarter.
Paulson & Co sold 78,101 Sarepta Therapeutics shares in Q2 2017, an estimated $2.31M.
Paulson & Co first reported a position in Sarepta Therapeutics in Q1 2017 and held it in 1 quarter.
Paulson & Co's Sarepta Therapeutics position peaked at $2.31M in Q1 2017.
189 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2017.

Based on Paulson & Co's 13F filing for Q2 2017, filed 14 Aug 2017.